Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Chang, Meiping ^a   Smith, Sarah ^a   Thorpe, Andrew ^a   Barratt, Michael J ^a   Karim, Farzana ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; NAPROXEN; PHENOXYBENZAMINE; ANALGESIC AGENT; DRUG DERIVATIVE; MANNITOL; MANNITYL OLEATE; MESSENGER RNA; OLEIC ACID;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MAPPING; GENETIC DATABASE; HYPERALGESIA; IMMUNE RESPONSE; MALE; MICROARRAY ANALYSIS; NERVE GROWTH; NERVE REGENERATION; NONHUMAN; OSTEOARTHRITIS; PREDICTION; PRIORITY JOURNAL; RAT; SPINAL GANGLION; STRUCTURE ACTIVITY RELATION; TEMPERATURE SENSITIVITY; UPREGULATION; ALGORITHM; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DISEASE MODEL; DNA MICROARRAY; DRUG EFFECT; GENETICS; INJECTION; METABOLISM; NOCICEPTIVE RECEPTOR; ORAL DRUG ADMINISTRATION; PAIN; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ALGORITHMS; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; GANGLIA, SPINAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INJECTIONS; MALE; MANNITOL; NAPROXEN; NOCICEPTORS; OLEIC ACIDS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAIN; PHENOXYBENZAMINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77956575047     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-56     Document Type: Article

References (61)

1. Vega-Avelaira D, Geranton S, Fitzgerald M. Differential regulation of immune responses and macrophage/neuron interactions in the dorsal root ganglion in young and adult rats following nerve injury. Molecular Pain 2009, 5:70. 10.1186/1744-8069-5-70, 2799401, 20003309.
2. Takeuchi H, Kawaguchi S, Mizuno S, Kirita T, Takebayashi T, Shimozawa K, Torigoe T, Sato N, Yamashita T. Gene Expression Profile of Dorsal Root Ganglion in a Lumbar Radiculopathy Model. Spine 2008, 33:2483-2488. 10.1097/BRS.0b013e318184acc3, 18978588.
3. Costigan M, Befort K, Karchewski L, Griffin R, D'Urso D, Allchorne A, Sitarski J, Mannion J, Pratt R, Woolf C. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neuroscience 2002, 3:16. 10.1186/1471-2202-3-16, 139981, 12401135.
4. Rodriguez Parkitna JKM, Kaminska-Chowaniec D, Obara I, Mika J, Przewlocka B, Przewlocki R. Comparison of gene expression profiles in neuropathic and inflammatory pain. J Physiol Pharmacol 2006, 57:14.
5. Rabert D, Xiao Y, Yiangou Y, Kreder D, Sangameswaran L, Segal MR, Hunt CA, Birch R, Anand P. Plasticity of gene expression in injured human dorsal root ganglia revealed by GeneChip oligonucleotide microarrays. Journal of Clinical Neuroscience 2004, 11:289-299. 10.1016/j.jocn.2003.05.008, 14975420.
6. Li X, Sahbaie P, Zheng M, Ritchie J, Peltz G, Mogil J, Clark JD. Expression genetics identifies spinal mechanisms supporting formalin late phase behaviors. Molecular Pain 2010, 6:11. 10.1186/1744-8069-6-11, 2831877, 20149257.
7. Xie WR, Deng H, Li H, Bowen TL, Strong JA, Zhang JM. Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience 2006, 142:809-822. 10.1016/j.neuroscience.2006.06.045, 1661830, 16887276.
8. Yang HY, Mitchell K, Keller JM, Iadarola MJ. Peripheral inflammation increases Scya2 expression in sensory ganglia and cytokine and endothelial related gene expression in inflamed tissue. J Neurochem 2007, 103:1628-1643. 10.1111/j.1471-4159.2007.04874.x, 17883394.
9. Hammer P, Banck MS, Amberg R, Wang C, Petznick G, Luo S, Khrebtukova I, Schroth GP, Beyerlein P, Beutler AS. mRNA-seq with agnostic splice site discovery for nervous system transcriptomics tested in chronic pain. Genome Res 2010, 20:847-860. 10.1101/gr.101204.109, 2877581, 20452967.
10. Stein CMM, Herz A. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav 1988, 31:155-151.
11. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S, Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van Becelaere K, Stevens RC, Cravatt BF. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chemistry & Biology 2009, 16:411-420.
12. Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB, Liimatta M, Beidler D, Smith S, Nomanbhoy TK, Cravatt BF. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorganic & Medicinal Chemistry Letters 2009, 19:2865-2869.
13. Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. European Journal of Pharmacology 2009, 617:59-67. 10.1016/j.ejphar.2009.06.058, 19580807.
14. Fendrick AM, Greenberg B. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopathic Medicine and Primary Care 2009, 3:1. 10.1186/1750-4732-3-1, 2646740, 19126235.
15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939, 17008526.
16. Ishimatsu-Tsuji Y, Soma T, Kishimoto J. Identification of novel hair-growth inducers by means of connectivity mapping. FASEB J 2009, fj.09-145292.
17. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111:5654-5662. 10.1182/blood-2007-11-126003, 2424160, 18305216.
18. Dixon WJ. Efficient analysis of experimental observations. Annual Review of Pharmacology and Toxicology 1980, 20:441-462. 10.1146/annurev.pa.20.040180.002301, 7387124.
19. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003, 114:323-334. 10.1016/S0092-8674(03)00570-1, 12914697.
20. Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M, El Hadri K. Inhibition of interleukin-1{beta}-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPAR{beta} and the proto-oncogene BCL-6. Mol Cell Biol 2007, 27:8374-8387. 10.1128/MCB.00623-07, 2169168, 17908795.
21. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON, Kawakami T. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol 2000, 165:1210-1219.
22. Maccarrone M, Battista N, Centonze D. The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Progress in Neurobiology 2007, 81:349-379. 10.1016/j.pneurobio.2006.11.006, 17276576.
23. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine & Growth Factor Reviews 2009, 20:185-191.
24. Liu DV, Maier LM, Hafler DA, Wittrup KD. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. Journal of Immunotherapy 2009, 32:887-894. 10.1097/CJI.0b013e3181b528da, 19816193.
25. Suzuki HOH. The atypical small GTPase RhoH: a novel role in T cell development. Nihon Rinsho Meneki Gakkai Kaishi 2008, 31:37-46.
26. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007, 13:492-497. 10.1038/nm1561, 17401376.
27. Ronni T, Payne KJ, Ho S, Bradley MN, Dorsam G, Dovat S. Human ikaros function in activated T cells is regulated by coordinated expression of its largest isoforms. Journal of Biological Chemistry 2007, 282:2538-2547. 10.1074/jbc.M605627200, 17135265.
28. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 11:114-120. 10.1038/ni.1837, 2864556, 20084069.
29. Rocca B, Spain LM, Puré E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. The Journal of Clinical Investigation 1999, 103:1469-1477. 10.1172/JCI6400, 408457, 10330429.
30. Algeciras-Schimnich A, Vlahakis SR, Villasis-Keever A, Gomez T, Heppelmann CJ, Bou G, Paya CV. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS 2002, 16:1467-1478. 10.1097/00002030-200207260-00003, 12131184.
31. Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K, Uemura Y, Aoki Y, Kaga S, Minota S, Tanaka T, Yamaguchi Y, Kobayashi T, Serizawa I. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clinical Immunology 2006, 120:247-259. 10.1016/j.clim.2006.05.006, 16797237.
32. Wolk KWE, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010, 32:17-31. 10.1007/s00281-009-0188-x, 20127093.
33. Fukumori T, Takenaka Y, Yoshii T, Kim H-RC, Hogan V, Inohara H, Kagawa S, Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003, 63:8302-8311.
34. Sturm A, Lensch M, Andre S, Kaltner H, Wiedenmann B, Rosewicz S, Dignass AU, Gabius H-J. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 2004, 173:3825-3837.
35. Tsujino S, Di Santo JP, Takaoka A, McKernan TL, Noguchi S, Taya C, Yonekawa H, Saito T, Taniguchi T, Fujii H. Differential requirement of the cytoplasmic subregions of γc chain in T cell development and function. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10514-10519. 10.1073/pnas.180063297, 27056, 10962026.
36. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007, 105:838-847. 10.1213/01.ane.0000275190.42912.37, 17717248.
37. Costigan M, Moss A, Latremoliere A, Johnston C, Verma-Gandhu M, Herbert TA, Barrett L, Brenner GJ, Vardeh D, Woolf CJ, Fitzgerald M. T-Cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci 2009, 29:14415-14422. 10.1523/JNEUROSCI.4569-09.2009, 2813708, 19923276.
38. Gao Y-J, Ji R-R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacology & Therapeutics 2010, 126:56-68.
39. White FA, Feldman P, Miller RJ. Chemokine signaling and the management of neuropathic pain. Molecular Interventions 2009, 9:188-195. 10.1124/mi.9.4.7, 2861804, 19720751.
40. Mitchell JD, Maguire JJ, Davenport AP. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. British Journal of Pharmacology 2009, 158:87-103. 10.1111/j.1476-5381.2009.00252.x, 2795236, 19519756.
41. Torresa R, Crolla SD, Vercollonea J, Reinhardta J, Griffithsa J, Zabskia S, Andersona KD, Adamsa NC, Gowena L, Sleemana MW, Valenzuelaa DM, Wieganda SJ, Yancopoulosa GD, Murphya AJ. Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain 2007, 130:267-278. 10.1016/j.pain.2007.01.036, 17379411.
42. Takashi Iwaia YI, Kodania R, Oka J. Neuromedin U inhibits inflammation-mediated memory impairment and neuronal cell-death in rodents. Neuroscience Research 2008, 61:113-119. 10.1016/j.neures.2008.01.018, 18336945.
43. Maina F, Hilton MC, Andres R, Wyatt S, Klein R, Davies AM. Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 1998, 20:835-846. 10.1016/S0896-6273(00)80466-3, 9620689.
44. Maina FHM, Ponzetto C, Davies AM, Klein R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev 1997, 11:3341-3350. 10.1101/gad.11.24.3341, 316818, 9407027.
45. Verdi J, Ahmadiani A. Finasteride, a 5[alpha]-reductase inhibitor, potentiates antinociceptive effects of morphine, prevents the development of morphine tolerance and attenuates abstinence behavior in the rat. Hormones and Behavior 2007, 51:605-610. 10.1016/j.yhbeh.2007.02.008, 17428486.
46. Jo SM DG, Schrøder HD, Suh SW. Depletion of vesicular zinc in dorsal horn of spinal cord causes increased neuropathic pain in mice. Biometals 2008:151-158.
47. Bruguerolle B, Labrecque G. Rhythmic pattern in pain and their chronotherapy. Advanced Drug Delivery Reviews 2007, 59:883-895. 10.1016/j.addr.2006.06.001, 17716777.
48. Kitanishi K, Igarashi J, Hayasaka K, Hikage N, Saiful I, Yamauchi S, Uchida T, Ishimori K, Shimizu T. Heme-binding characteristics of the isolated PAS-A domain of mouse Per2, a transcriptional regulatory factor associated with circadian rhythms. Biochemistry 2008, 47:6157-6168. 10.1021/bi7023892, 18479150.
49. Raz-Prag D, Zeng Y, Sieving PA, Bush RA. Photoreceptor protection by adeno-associated virus-mediated LEDGF expression in the RCS rat model of retinal degeneration: probing the mechanism. Invest Ophthalmol Vis Sci 2009, 50:3897-3906. 10.1167/iovs.08-3153, 2744960, 19324854.
50. Wu C, Qiu R, Wang J, Zhang H, Murai K, Lu Q. ZHX2 interacts with ephrin-B and regulates neural progenitor maintenance in the developing cerebral cortex. J Neurosci 2009, 29:7404-7412. 10.1523/JNEUROSCI.5841-08.2009, 2759685, 19515908.
51. Kim T-A, Jiang S, Seng S, Cha K, Avraham HK, Avraham S. The BTB domain of the nuclear matrix protein NRP/B is required for neurite outgrowth. J Cell Sci 2005, 118:5537-5548. 10.1242/jcs.02643, 16306221.
52. Jones JO, B EC, Huang Y, Feau C, Kiplin Guy R, Yamamoto KR, Byron H, Marc DI. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009, 106:7233-7238. 10.1073/pnas.0807282106, 2678452, 19363158.
53. Kibaly C, Meyer L, Patte-Mensah C, Mensah-Nyagan AG. Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J 2008, 22:93-104. 10.1096/fj.07-8930com, 17720801.
54. Varoli L, Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Bedini A, Fazio N, Spampinato S. Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008, 18:2972-2976.
55. AM T. Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. Recent Pat CNS Drug Discov 2008, 3:94-103. 10.2174/157488908784534621, 18537768.
56. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A. Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. Journal of Biological Chemistry 2001, 276:31279-31284. 10.1074/jbc.M104167200, 11395517.
57. Ghostine SY, Comair YG, Turner DM, Kassell NF, Azar CG. Phenoxybenzamine in the treatment of causalgia. Journal of Neurosurgery 1984, 60:1263-1268. 10.3171/jns.1984.60.6.1263, 6726371.
58. Mario AI, Grigory K. Treatment of Complex Regional Pain Syndrome Type I with oral phenoxybenzamine: rationale and case reports. Pain Practice 2008, 8:125-132. 10.1111/j.1533-2500.2007.00170.x, 18194348.
59. Cicero TJ, Meyer ER, Smithloff BR. Alpha adrenergic blocking agents: antinociceptive activity and enhancement of morphine-induced analgesia. Journal of Pharmacology and Experimental Therapeutics 1974, 189:72-82.
60. Spiehler VRRL. Agonist--antagonist properties of phenoxybenzamine in antinociception and opiate dependence tests. Eur J Pharmacol 1979, 55:389-395. 10.1016/0014-2999(79)90113-4, 572775.
61. Hendershot LC, Forsaith J. Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesic and nonalgesics. Journal of Pharmacology and Experimental Therapeutics 1959, 125:237-240.